Epigenetic Therapy as a Putative Molecular Target to Modulate B Cell Biology and Behavior in the Context of Immunological Disorders

Figure 4

Schematic illustrating the impact of iHDAC on the peritoneal physiology and B1 cell behavior. Under normal conditions (control), the peritoneal cavity is composed of a diverse set of cell types including B lymphocytes (B1 and B2), monocytes, macrophages, and mast cells. The mesenteric lamina presents high cellular density (blue dots). After inhibition of HDAC activity (iHDAC), the mesenteric lamina displays a lower cell density coupled to the increasing amount of B1 cells, degranulated mast cells, and elongated macrophages. In this scenario, iHDAC might emerge as a tractable epigenetic therapy to modulate the physiology of the peritoneal cavity in addition to modulating B1 cells, mast cells, and macrophage biology and behavior.